L E T T E R S T O T H E E D I T O R
The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I
Abstract
In this study, we aimed to investigate the anti-melanoma effects and the JAK2/STAT3 pathway-related mechanism of action of atractylenolide I in human melanoma cells. Our results showed that atractylenolide I effectively reduced viability, induced apoptosis and inhibited migration of melanoma cells. Meanwhile, atractylenolide I decreased the protein expression levels of phospho-JAK2 and phospho-STAT3, and in turn downregulated the mRNA levels of STAT3-targeted genes, including Bcl-xL, MMP-2 and MMP-9. Furthermore, the cytotoxic effect of atractylenolide I was attenuated in STAT3-overactivated A375 cells. These findings indicate that inhibition of JAK2/STAT3 signalling contributes to the anti-melanoma effects of atractylenolide I.
| BACKGROUND
Malignant melanoma is the most aggressive skin cancer. Although immunotherapies, chemotherapies and targeted therapies have shown encouraging clinical results in treating melanoma, the 5-year survival rate of patients with metastatic melanoma is only 17%. [1] New targeted therapies for melanoma management are needed.
Constitutively activated/phosphorylated signal transducer and activator of transcription 3 (STAT3) plays a key role in promoting melanoma growth, metastasis, angiogenesis and immune evasion. [2] Activation of janus kinase 2 (JAK2) is widely observed and related to STAT3 signalling in melanoma. [3] Targeting the JAK2/STAT3 pathway has been proposed as a therapeutic strategy against melanoma.
Atractylenolide I (AT-I), a sesquiterpene derived from atractylodis macrocephalae rhizoma (AMR, the dried rhizome of Atractylodes macrocephala), possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. [4] In a clinical study, oral administration of AT-I alleviated symptoms of gastric cancer cachexia in patients without overt adverse effects. [5] Pharmacokinetic studies demonstrated that AT-I can be easily absorbed but slowly eliminated in rats after oral administration, suggesting a good oral bioavailability. [6] All these indicate that AT-I is a druggable compound. Our previous studies showed that AT-I inhibited cell survival and migration in mouse B16 melanoma cells, [7] suggesting a potential for AT-I to treat melanoma. However, the underlying mechanism of action for AT-I's anti-melanoma effects is not fully understood. AT-II, a structural homolog of AT-I, exerted
anti-melanoma effects partially by inhibiting STAT3 signalling. [8] In this study, we aimed to investigate the involvement of the JAK2/ STAT3 pathway in the anti-melanoma effects of AT-I in human melanoma cells.
| QUESTION ADDRESSED
Is the JAK2/STAT3 pathway involved in AT-I-exerted anti-melanoma effects in human melanoma cells?
| EXPERIMENTAL DESIGN
AT-I (purity above 99% as determined by HPLC) was prepared as described. [7] Human A375, Hs294T and SK-MEL-5 melanoma cells cultured in DMEM supplemented with 5% FBS were exposed to in- Establishment of the stable cell lines and the assays was performed as described. [9] The expression level of phosphorylated STAT3 in the established A375 STAT3C stable cells was higher than that in A375 NC stable cells . [9] for developing AT-I as a novel anti-melanoma agent. Activation of JAK2/STAT3 has been linked to immune evasion in melanoma. [10, 11] Whether AT-I reprograms the immune-suppressive melanoma microenvironment by inhibiting JAK2/STAT3 signalling is a question to be addressed.
| RESULTS
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Cytotoxicity, apoptosis, metastasis, molecular pathways, targeted therapy F I G U R E 2 Effects of AT-I on JAK2/STAT3 signalling in human A375 melanoma cells. (A) AT-I suppressed the phosphorylation of JAK2 and STAT3 in A375 cells. Cells were treated with 0, 50 and 100 μM of AT-I for 48 h and lysed using RIPA buffer. Protein expression levels of total and phosphorylated JAK2 (Tyr1007/Tyr1008) and STAT3 (Tyr705) were respectively examined by Western blotting. β-actin was included as the internal control. Representative results from three independent experiments were shown. Relative protein levels were shown as mean ± SD. *P < 0.05 and **P < 0.01 as compared to control. (B) AT-I downregulated the mRNA levels of STAT3-targeted genes in A375 cells. Cells were treated with AT-I at the concentrations of 0, 50, 100 μM, respectively. Total RNA was extracted by Trizol reagent and reversely transcripted with MMLV reverse transcriptase. The mRNA expression levels of Bcl-xL, MMP-2 and MMP-9 were examined by quantitative real-time PCR. Relative mRNA expression level for each gene was evaluated using the 2 −ΔΔCt method, where
ΔCt is the threshold cycle number of a gene in normalization to that of the endogenous control GAPDH, and ΔΔCt is the difference between a treatment and the control group. Data were shown as mean ± SD from three independent experiments. In both (A) and (B), statistical analysis was performed by one-way ANOVA followed by Student's t test, *P < 0.05 and **P < 0.01 as compared to control. 
| BACKGROUND
The Warburg effect describes the phenomenon whereby cancer cells generate energy predominantly via glycolysis even if sufficient oxygen is present. At first, it seems paradoxical that tumors would use the relatively inefficient glycolytic pathway instead of oxidative phosphorylation (OXPHOS) for energy production. However, there are several explanations for reprogramming the pathway of ATP generation in cancer cells.
A major inducer of the glycolytic response is the transcription factor hypoxia-inducible factor-1α (HIF1α), which mediates a pleiotropic reaction by inducing a plethora of gene products, including glucose
